50411-26-2

Usage

Uses

Used in Pharmaceutical Industry:
1-AMINO-3-PHENYL-PROPAN-2-OL is used as a decongestant for its ability to constrict blood vessels in the nasal passages, providing relief from congestion and improving breathing.
1-AMINO-3-PHENYL-PROPAN-2-OL is used as an appetite suppressant due to its potential to stimulate the central nervous system, leading to decreased appetite.
Used in Neurodegenerative Disease Treatment Research:
1-AMINO-3-PHENYL-PROPAN-2-OL is studied as a potential treatment for neurodegenerative diseases, although further research is needed to establish its efficacy and safety.
Used in Organic Synthesis:
1-AMINO-3-PHENYL-PROPAN-2-OL serves as an intermediate in organic synthesis, contributing to the development of various chemical compounds and pharmaceuticals.

Upstream product

• 50353-47-4 phenyl acetaldehyde cyanohydrin 
• 300-57-2 allylbenzene 
• 7677-24-9 trimethylsilyl cyanide 
• 122-78-1 phenylacetaldehyde 
• 132871-52-4 1-azido-2-hydroxy-3-phenylpropane 
• 19881-97-1 3-phenylpropane-1,2-diol 
• 95242-60-7 1-Benzyl-3-benzyloxy-4-phenyl-azetidin-2-one 
• 86863-62-9 (3S,4R)-1-Benzyl-3-benzyloxy-4-phenyl-azetidin-2-one 
• 5396-65-6 1-chloro-3-phenylpropan-2-ol 
• 86863-69-6 (2R,3R)-1-Benzyl-3-benzyloxy-2-phenyl-azetidine 
• 95242-66-3 (2R*,3R*)-1-benzyl-2-phenyl-3-(benzyloxy)azetidine 
• 4436-24-2 1,2-epoxy-3-phenylpropane 

Downstream Products

• 63009-94-9 1-methylamino-3-phenyl-propan-2-ol 
• 78515-40-9 1-Phenyl-2-(benzenesulfonyloxy)-3-benzenesulfonamidopropane 
• 134480-92-5 1-[2-(Isochroman-1-yl)-1-methylethylamino]-3-phenyl-2-propanol 
• 906087-10-3 N-(3-(((2-hydroxy-3-phenylpropyl)amino)carbonyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridine-2-carboxamide 
• 900522-79-4 (6S)-4-aza-8-methyl-1-phenyl-6-phthalimido-5-oxononan-2-ol 
• 1047656-67-6 N-(2-hydroxy-3-phenylpropyl)-6-(1'H-spiro[indene-1,4'-piperidin]-1'-yl)pyridazine-3-carboxamide 
• 1276028-07-9 C₂₃H₂₉N₅O₃ 
• 845909-95-7 2-(2-hydroxy-3-phenyl-propylamino)-3-methyl-5-naphthalen-2-yl-6-pyridin-4-yl-3H-pyrimidin-4-one 
• 1407180-55-5 2-isopropyl-5-benzyl-1,3-oxazolidine 
• 78515-41-0 3-Phenyl-2-bromo-1-benzenesulfonamidopropane 
• 118499-04-0 1-[(6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]-3-phenylpropan-2-ol 
• 167867-56-3 (S)-2-Amino-N¹-[(R)-2-((3S,4aS,8aS)-3-tert-butylcarbamoyl-octahydro-isoquinoline-2-sulfonyl)-3-phenyl-propyl]-succinamide 
• 167938-68-3 (S)-2-Amino-N¹-[(S)-2-((3S,4aS,8aS)-3-tert-butylcarbamoyl-octahydro-isoquinoline-2-sulfonyl)-3-phenyl-propyl]-succinamide 

Relevant academic research and scientific papers

PYRAZOLOPYRAZINES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (IIa) or (IIb), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph,codrug, cocrystal,prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Binaphthyl-based dicationic peptoids with therapeutic potential

(Figure Presented) Superbugs stalled! Two newly designed synthetic dicationic peptoids (see one example; red O, blue N, green Cl) show promising in vitro bactericidal activity against a range of Gram-positive pathogens, including organisms resistant to vancomycin, methicillin, and linezolid, with only slow development of resistance. Moreover their potency is maintained in vivo.

INHIBITORS OF AKT ACTIVITY

Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

INHIBITORS OF AKT ACTIVITY

Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

INHIBITORS OF Akt ACTIVITY

Invented are novel thiophene compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

PEPTIDIC COMPOUNDS

The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, whe

Thiazolidine and oxazolidine derivatives, their preparation and their medical use

Compounds of formula (I): STR1 and salts, esters and solyates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.

Synthesis of Peptidosulfinamides and Peptidosulfonamides: Peptidomimetics Containing the Sulfinamide or Sulfonamide Transition-State Isostere

Synthetic routes are described toward the preparation of α- as well as β-substituted aminoethanesulfinyl chlorides, starting from either an aldehyde or from an amino acid derivative.The sulfinyl chlorides are used as building blocks for the preparation of homochiral α- or β-substituted sulfinamide and sulfonamide transition-state isosteres.The methodology has been applied to the synthesis of peptidosulfonamide peptidomimetics such as a hapten needed for the generation of antibodies and potential HIV protease inhibitors.In addition, the β-substituted aminoethanesulfinyl chlorides were used as building blocks for the preparation of a tetrapeptidosulfonamide, which can be considered as a biopolymer mimetic, employing a repetition of a cycle of three reactions: coupling of the sulfinyl chloride to the N-terminus of the growing peptidosulfonamide, oxidation to the sulfonamide, and deprotection of the N-terminus.